Concentra Group Holdings Parent, Inc. (CON) stock intrinsic value fair value estimate & owner earnings analysis

Concentra is the largest occupational health provider in the United States by number of locations. At the end of 2025 it ran 628 stand-alone medical centers in 41 states and 411 clinics inside employers' worksites in 44 states, plus a telemedicine service. About 61% of 2025 revenue came from treating workplace injuries paid through state workers' compensation systems; most of the rest comes from employer services such as pre-employment physicals, drug and alcohol testing and Department of Transportation exams. Prices for injury care are largely set by state fee schedules, and the company reports that reimbursement rates have risen about 3% a year on average since 2016. Centers are spread widely, with about 16% in California, 16% in Texas, 6% in Florida, 5% in Pennsylvania and 4% in Colorado. Concentra was owned by Select Medical until its July 2024 public listing. To fund a $1.54 billion dividend to Select, it borrowed $850 million on a term loan and issued $650 million of 6.875% notes due July 15, 2032. In 2025 it spent $333 million buying Nova Medical Centers (67 centers in five states, $265 million) and Pivot Onsite Innovations (over 240 worksite clinics, $54 million), adding to the term loan to pay for Nova. How we measured earnings. We start from operating cash flow, strip out swings in working capital, and subtract stock-based pay and the capital spending needed to keep the existing centers running (we treat only spending tied to revenue growth as optional). On that basis owners earned $1.85 per share in 2022, $1.84 in 2023, $1.58 in 2024 and $1.46 in 2025. The decline is almost entirely interest: cash interest rose from $31 million in 2022 to $109 million in 2025 because of the separation debt. Before interest, the business produced about $223 million, $236 million, $230 million and $296 million in those four years. Amortization of acquired customer relationships ($25.9 million in 2025) is a non-cash charge and is added back; because those relationships wear out, their decay is carried in the bear case rather than by cutting the earnings level. Starting point. The business changed shape in 2024 and 2025, so older years understate it. We use about $300 million a year of cash before interest as the normal level, close to 2025's $296 million. That 2025 figure carried one-time separation and acquisition costs and only part-year contributions from Nova and Pivot, but it is a single year, so we did not raise the level further. Pre-interest cash flow grew 29% in 2025, mostly from acquisitions. Our base case assumes 6% for 2026. The first half of 2026 supports this: pre-tax income was $159.0 million against $115.2 million a year earlier, on revenue up 11.8%. Base case ($34.61 per share). Cash flow before interest reaches about $318 million in 2026 and then grows 2% a year, below the roughly 3% annual rise in reimbursement rates, because wages and other costs also rise. That takes it to about $380 million by 2035. After that it holds flat. State laws require employers to provide injury care, and federal rules require transportation worker exams, so the need for the service persists. We give no credit for future acquisitions or new centers. The business is worth about $6.08 billion. Partners in jointly owned centers are owed about $0.15 billion of that, and net debt is about $1.49 billion: roughly $1.59 billion of borrowings, less about $128 million of cash above operating needs, plus about $28 million for the notes costing more than 6% until 2032. That leaves about $4.43 billion for shareholders. Bear case ($17.52 per share). The company itself warns that job cuts reduce both workers' compensation claims and pre-employment testing. In this case 2026 comes in near $300 million, then a downturn cuts cash flow to about $240 million in 2027. It recovers only to about $260 million and stays there, with no pricing gains because fee schedules lag. After 2035 it shrinks 1.5% a year, reflecting the long-term fall in workplace injury rates and the fading of acquired relationships. Cash before interest still covers the roughly $100 million interest bill about 2.4 times at the low point, so the July 2029 revolver, the July 26, 2031 term loan and the 2032 notes look refinanceable even here. The business is worth about $3.83 billion. Less about $0.10 billion owed to partners and $1.49 billion of net debt, that leaves about $2.24 billion for shareholders. Bull case ($43.99 per share). The 2025 staffing efficiencies (cost of services fell from 72.2% to 71.7% of revenue) and first-half 2026 momentum hold, so 2026 reaches about $345 million. Reimbursement increases near their historical 3% pace plus modest gains at the newly acquired centers lift cash flow 3.5% a year to about $470 million by 2035, flat thereafter. The business is worth about $7.31 billion; less $0.18 billion owed to partners and $1.49 billion of net debt, shareholders are left with about $5.63 billion. What could make this wrong. The debt makes the shares more sensitive than the business. About $940 million of the borrowings float with short-term rates, so a 1% rise adds roughly $9 million of annual interest. The value also depends on states continuing to raise fee schedules; a freeze in California or Texas would hurt. The company has bought growth before, and buying more with borrowed money would raise risk without, on our numbers, adding value unless the price is right. We could not separate how much of 2025's improvement came from Nova and Pivot versus the existing centers, because the filings do not break it out.